

Product Specifics:	Gammaplex	Privigen	Hizentra	Flebogamma	Gammagard Liquid	Gammagard S/D	Gammaked / Gamunex-C	Octagam
Sizes	5g, 10g, 20g	5g, 10g, 20g, 40g	1g, 2g, 4g, 10g	5%: 2.5g, 5g, 10g, 20g 10%: 5g, 10g, 20g	1g, 2.5g, 5g, 10g, 20g, 30g	5g, 10g	1g, 2.5g, 5g, 10g, 20g	5%: 1g, 2.5g, 5g, 10g 10%: 2g, 5g, 10g, 20g
Storage	Room temperature (25°C) (77°F) - 36 months Do not freeze. Do not shake.	Room temperature (25°C) (77°F) Protect from light. Do not freeze. Do not shake.	Room temperature (25°C) (77°F) Do not freeze. Keep vials in storage box until use.	2° to 25°C (36° to 77°F) Do not freeze. Do not shake.	2° to 8°C (36° to 46°F) Do not freeze. Do not shake.	Not to exceed 25°C (77°F), Avoid freezing. Do not shake.	2° to 8°C (36° to 46°F). Do not freeze.	2° to 8°C (36° to 46°F) for 24 months. Do not freeze.
Form	Liquid	Liquid	Liquid	Liquid	Liquid	Lyophilized	Liquid	Liquid
Reconstitution Fluid	N/A	N/A	N/A	N/A	N/A	Sterile Water for Injection	N/A	N/A
Concentration Options	5% and 10%	10%	20%	5% and 10%	10%	5% or 10%	10%	5% and 10%
Indications	PI and ITP	PID + ITP	PID	PID	PID + MMN	PID + ITP + CLL + Kawasaki disease	PID + ITP + CIDP	5%: PID 10%: ITP
Contraindications	History of anaphylactic or severe systemic reactions to human immunoglobulin. IgA deficient patients with antibodies against IgA and a history of hypersensitivity.	IgA deficiency with antibodies to IgA. Also contraindicated in hyperprolinemia patients due to stabilizer: L-proline.	IgA deficiency with antibodies to IgA. Also contraindicated in hyperprolinemia patients due to stabilizer: L-proline.	IgA deficiency with antibodies to IgA. Patient intolerant to sorbitol (ie. Intolerant to fructose).	History of anaphylactic or severe systemic reactions to human immunoglobulin. IgA deficiency with antibodies to IgA	Selective IgA deficiency where IgA deficiency is only abnormality of concern.	IgA deficiency with antibodies to IgA	IgA deficiency with antibodies to IgA History of anaphylactic or severe reactions to human immunoglobulin
Infusion Rates (Refer also to full prescribing information).	5%: Initial: 0.5mg/kg/min (0.01 mL/kg/min) for 15 mins, increase gradually every 15 mins to 4mg/kg/min (0.08mL/kg/min) 10%: Initial: 0.5mg/kg/min (.005mL/kg/min) for 15 mins, Increase gradually every 15 mins to 8mg/kg/min (0.08 mL/kg/min)	Initial: 0.5mg/kg/min Maximum: 4mg/kg/min	Subcutaneous only: Not for intravenous administration. Injection sites: abdomen, thighs, upper arms, and/or lateral hip. Initial Infusion: 15mL/hr/inj site. Subsequent infusions may be increased as tolerated to 25mL/hr/site at a maximum rate of 50mL/hour for all sites combined.	5%: 0.01 mL/kg body weight/minute (0.5 mg/kg body weight/minute) up to a maximum of 0.10 mL/kg/minute (5 mg/kg/minute).	Intravenous (IV): Initial: 0.8mg/kg/min Maximum: 8-9mg/kg/min Subcutaneous (SC): Initial: 1.37 x current IV dose in mg/kg per IV dose interval in weeks Maximum: 20 to 30mL/hr/site	Use a 5% solution at 0.5 mL/kg/hr. Patients who tolerate the 5% solution at up to 4 mL/kg/hr can be infused with 10% solution starting at 0.5 mL/kg/hr up to 8 mL/kg/hr.	Intravenous (IV): Initial: 1mg/kg/min Maximum: 8mg/kg/min Subcutaneous (SC): Initial: 1.37 x current IV dose in mg/kg per IV dose interval in weeks Maximum: 20mL/hr/site	5% Initial: 0.01mL/kg/minute (0.5mg/kg/minute) Maintenance infusion rate: 3.33gm/kg/min (if tolerated) 10% Initial: 1.0mg/kg/min Maximum: Up to 12.0mg/kg/min
Other Administration Information	Infuse product at approximately room temperature. Infuse with set preferable fitted with an in-line 15-20 micron filter.	If dilution is required, may be diluted in 5% dextrose in water (D5/W).	Warm to room temperature. Discard unused product immediately after use.	Warm to room temperature if refrigerated. Use pooled product promptly (may transfer into empty sterile IV container using aseptic technique).	If dilution is required, may be diluted with 5% dextrose in water (D5/W). Warm to room temperature before infusing.	If refrigerated, warm to room temperature prior to infusion.	If dilution is required, may be diluted with 5% dextrose in water (D5/W). May be pooled in either glass or plastic. Warm to room temperature prior to infusion.	Warm to room temperature if refrigerated prior to infusion.
Compatibility Issues	Administer separately from other drugs/medications.	Infuse product by separate line without mixing other medications or fluids.	Should not be mixed with other medicinal products.	Do not dilute with other IV fluids. Do not add any medications or IV fluids to product infusion container. Infuse by separate IV line.	Infuse product by separate line without mixing other IV fluids or medications. Do not use NS 0.9% as a diluent.	Administer separately from other drugs/medications.	Infuse product by separate line without mixing with other IV fluids or medications. If administered through indwelling catheter, flush with D5W or NS before and after infusing product.	Administer separately from other drugs or medications. Flushing: any normal infusion solution (i.e. D5W/saline).
IgA Content	5%: <10 µg/mL 10%: <20 µg/mL	≤25 mcg/mL	≤50mcg/mL	5% - <50 µg/mL 10% - <100 µg/mL	37 µg/mL	≤2.2 µg/mL (5% concentration)	46 µg/mL	5%: <200 µg/mL 10%: <106 µg/mL
Sugar Content	5%: D-Sorbitol 10%: no sugar; stabilized with Glycine	No sugar; stabilized with a nonessential amino acid: 250 mmol/L L-proline	None	5%: 5% D-Sorbitol 10%: 50mg/mL D-Sorbitol	No sugar; stabilized with glycine.	2% glucose (5% concentration)	No sugar; stabilized with glycine.	5%: Maltose 100mg/mL 10%: Maltose 90mg/mL
Sodium Content	5%: 30-50mmol/L 10%: <30mM Sodium Chloride	Trace amounts	Trace Amounts	<3.2 mEq/L (<0.02%)	None detected	Approximately 8.5 mg/mL sodium chloride	Trace amounts	≤30 mmol/L
Osmolarity / Osmolality	5%: 420-500 mOsm/kg 10%: 240-280 mOsmol/kg	320 mOsmol/kg (240 to 440 range)	380 mOsmol/kg	240-370 mOsmol/kg	240-300 mOsmol/kg	636 mOsmol/L (5%) 1250 mOsmol/L (10%)	258 mOsmol/kg	310-380 mOsmol/kg
Latex in product stopper	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free
Latex in diluent stopper	N/A	N/A	N/A	N/A	N/A	Contains Latex	N/A	N/A

IMPORTANT NOTICE - The information provided herein is a summary of available information only. This summary is to be used as a general educational tool and is not intended for use as a guideline for clinical evaluations. Such evaluations (including, but not limited to, initial and/or subsequent dosing, conversion from specific product brands, etc.) should utilize a thorough review of appropriate clinical data. Product package inserts are the primary source of information. Please see full Prescribing Information before prescribing.